RECEIVED
JUL 17 2000
TECH CENTER 1600/2900

~~214. The method of claim 1, wherein density of the cells is at least 10^9 cells/liter.~~

~~215. The method of claim 1, wherein density of the cells is at least 10^{10} cells/liter.~~

F1 cont

~~216. The method of claim 22, wherein density of the cells is at least 10^9 cells/liter.~~

~~217. The method of claim 22, wherein density of the cells is at least 10^{10} cells/liter.~~

Please cancel claims ~~2~~, ~~3~~, ~~5~~, ~~7~~, ~~14~~, ~~16~~, ~~17~~, ~~154~~ without prejudice or disclaimer.

Please amend claims 1, 8, 22 and 155 as follows:

1. (Amended) A method for selectively stimulating proliferation and differentiation of T lymphoid cells to generate[generating] a high density of clinically relevant numbers of T lymphoid cells, comprising:

collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;

F2

treating the cells are under conditions whereby *ex vivo* differentiation of the cells into Th1, Th1-like, Th2-like or Th2 cells is induced; and

contacting, in the absence of exogenous interleukin-2, the material with two or more activating proteins specific for cell surface proteins present on cells in the material and in an amount sufficient to induce *ex vivo* cell expansion, whereby the cells expand to [clinically relevant numbers at a density of] at least about [10^9] 10^{10} cells regulatory cells of one predominant phenotype [in a volume of about a liter].

8. (Amended) The method of claim 1, wherein the expanded cells are predominantly Th1 or Th2[or Th3] cells.

22. (Twice Amended) A method for generating clinically relevant cell numbers of regulatory T lymphoid cells, comprising:

(a) collecting material containing mononuclear T lymphoid cells from a mammal;

(b) activating the T lymphoid cells to alter their cytokine production profile by causing differentiation of the cells to regulatory cells; and

(c) inducing cell proliferation and expanding the cells under conditions that produce [high cell density of] at least about 10^{10} cells/liter [10^9 cells/liter and produce clinically relevant number] of a homogeneous population of regulatory T lymphoid cells.

155. (Amended) A method for generating clinically relevant numbers of regulatory T lymphoid cells for autologous cell therapy, comprising:

(a) collecting material comprising body fluid or tissue containing mononuclear cells from a mammal;

(b) treating the cells to induce differentiation of mononuclear cells into regulatory T cells, wherein regulatory T cells are mononuclear cell that have the ability to control or direct an immune response, but do not act directly as effector cells in the response; and

(c) contacting the resulting differentiated cells with [one] two or more activating proteins specific for cell surface proteins present on the cells in an amount sufficient to induce *ex vivo* cell expansion, whereby clinically relevant numbers of regulatory cells for autologous cell therapy are generated.

REMARKS

A check for the fee for a three month extension of time accompanies this response. Any fee that may be due in connection with this application may be